Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Total Liabilities
Everything the company owes to creditors and other parties.
Zura Bio LimitedNASDAQ: ZURA
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 44.3% from a year ago
Total liabilities stood at $11.75M at the end of Q1 FY2026, down 44.3% from a year earlier and down 5.4% from the prior quarter. Over 3 fiscal years it compounded at -23.1% a year.
Context
- Total liabilities amounted to 5.1% of total assets at the end of Q1 FY2026, down 7.1 pp from a year earlier.
- Total liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -44.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 12.41M USD
- Year-over-year change
- -36.4%
- 4-year CAGR
- +4.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.41M | -36.4% |
| FY2024 | 2024-12-31 | 19.51M | -8.4% |
| FY2023 | 2023-12-31 | 21.29M | -22.1% |
| FY2022 | 2022-12-31 | 27.32M | +163.9% |
| FY2021 | 2022-03-31 | 10.35M | — |
Total Liabilities vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 total liabilities of $11.75M is the 9th highest of the 11 companies compared; the peer median is $35.13M.
- Its year-over-year change of -44.3% is the 9th highest of 11, against a peer median of -3.2%.
- Total liabilities amounts to 5.1% of total assets for ZURA, versus a peer median of 20.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.29B | +93713.8% | +2.6% | 3.9% | |
| Mar 2026 | $298.58M | -6.8% | -8.8% | 134.4% | |
| Mar 2026 | $198.12M | -13.7% | +53.9% | 63.0% | |
| Mar 2026 | $54.05M | -44.9% | -31.8% | 22.0% | |
| Mar 2026 | $36.9M | -48.7% | +38.5% | 15.7% | |
| Mar 2026 | $33.36M | +0.3% | -0.9% | 18.8% | |
| Mar 2026 | $33.03M | +0.8% | -9.0% | 51.4% | |
| Mar 2026 | $28.88M | +17.6% | -12.7% | 21.4% | |
ZURAZura Bio Limited | Mar 2026 | $11.75M | -44.3% | -23.1% | 5.1% |
| Mar 2026 | $11.6M | +83.1% | -38.2% | 11.8% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $5.3M | -26.2% | -71.5% | 4.9% |
| Peer median (excluding ZURA) | $35.13M | -3.2% | -8.9% | 20.1% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.